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Summary
In Africa and across the globe, the Covid-19 
pandemic has demonstrated the fragility of 
manufacturing supply chains, particularly in 
relation to essential commodities for healthcare.  
It has forced a global recognition of local 
manufacturing and supply chains’ centrality to 
local health security. This report summarises 
findings from a webinar, hosted on 28 October 
2020, which brought African manufacturers 
in health-related industries together with 
engaged academics in India and Africa, and 
other professionals working on the regulation, 
distribution and industrial support in African 
countries. The webinar aimed to capture the 
immediate experience of manufacturing under 
Covid-19 conditions in Africa and India and to 
draw lessons for policy.
The central argument is that broad-based 
industrial development is critical for local health 
security in Africa; this is the post-Covid-19 
medium-term challenge. As the pandemic 
unfolded, African manufacturers experienced the 
collapse of input supply chains, with vertiginous 
increases in imported input prices alongside 
escalating freight costs. Buyers’ payments 
slowed, exacerbating the financial squeeze on 
manufacturers. Lack of local input suppliers, 
especially in active pharmaceutical ingredients 
(APIs), medical grade fabric and plastics, and 
high-quality packaging, alongside weak local 
testing and accreditation capability, constrained 
local manufacturers’ outputs just as demand 
escalated. Nevertheless, the webinar identified 
an impressive range of scaling up and product 
innovation by African manufacturers to meet local 
pandemic needs.
Core lessons
Four core lessons, were identified. First, 
broadening and deepening the African industrial 
base is essential to reduce the concentration risk 
that arises from reliance on a small number of 
largely external suppliers of essential items. More 
local suppliers, new industrial collaborations 
and stronger backward linkages in the health 
industries are all required. Industry associations 
can act as brokers or intermediary institutions, 
facilitating knowledge renewal and promoting 
linkages between critical sectors.
Second, this industrial deepening requires better 
collaborative capabilities among multiple actors 
such as the private sector and governments, 
including through public-private partnerships 
(PPPs). Countries that reacted fast to the 
pandemic crisis have displayed capacity to 
collaborate, co-learn and co-solve old and 
new problems across industry, academia and 
government: this momentum must be sustained. 
Third, this in turn requires strengthening and 
re-thinking the role of the public health system 
in stimulating local industrial development, 
through innovative procurement, assured 
markets for local manufacturers, and shaping 
technological upgrading. Local health systems 
can and must develop more agency, power 
and leverage in shaping local industrial and 
technological development. 
Finally, centres of excellence can provide the 
infrastructure that is needed in African 
regions to support quality improvement and 
technological capability upgrading in emerging 
industrial clusters. This includes enhancing 
scarce skills, providing patient funding at scale, 
market development, innovation and supply 
chain strengthening.
Indian experience during the pandemic confirms 
the importance of a broad industrial base, sustained 
local engineering knowledge and opportunities 
for rapid adaptation and collaboration across 
industrial sectors. Negative lessons included the 
relative neglect in India pre-Covid-19 of service 
sectors such as cold-chain storage and delivery. 
Indian experience also identifies the importance of 
active contestation for policy effectiveness, through 
challenging engagement in policy debate by diverse 
stakeholders. Finally, India-Africa collaboration 
remains relatively weak: African market integration 
and policy shifts could improve the incentives for 
Indian investment in Africa in the medium term. 
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Covid-19 has been a wake-up call for the 
importance of local manufacturing for health 
in Africa, but what will it take to stay awake? 
Participants identified priorities for sustained 
investment in institutions to support industrial 
development at national and regional levels. These 
included stronger testing-regulation-accreditation 
processes for new and upgraded outputs, as 
well as better industrial finance to support 
innovation and technological development. Policy 
capabilities for active problem-solving could be 
strengthened by effective contestation and policy 
learning, including an active role for industrial 
associations. The report concludes by identifying 
further research needed to support integration 
of industrial, institutional and health policies 
for managing public health security risks in 
African countries. 
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1. Introduction
The impact of the Covid-19 pandemic in Africa 
has exacerbated health and socioeconomic 
inequalities, severely stressed national health 
systems, and significantly slowed down 
economic growth attained by sub-Saharan 
African countries in the past two decades. It 
has opened up debates exploring the tough 
recovery roads ahead, against the backdrop of 
the economic impact of pandemic lockdowns and 
depleted local pharmaceutical capabilities, but 
also in the light of some positive experiences of 
adaptation and local response. 
These debates have echoed, and pulled to 
centre stage, the importance and fragility of 
local manufacturing suppliers to healthcare. 
As import-dependent African countries saw 
their international supply chains collapse, local 
manufacturers attempted to fill the gaps with 
varying degrees of success. Supply chains for 
essential commodities including medicines and 
vaccines, diagnostics, medical devices, personal 
protective equipment (PPE), swabs and hand 
sanitisers, among others, are no longer seen as just 
a technical matter of buying available inputs for a 
health system; globally they are now understood 
as central matters of health security. The 
importance of local capabilities, and the proximity 
of manufacturers to their health systems, has 
crystallised in a moment of great need.
A webinar organised in October 2020, facilitated 
by the authors of this report and hosted by 
ODI, aimed to capture some of this immediate 
experience of manufacturing under Covid-19 
conditions in both Africa and India, and to 
draw lessons for policy. It brought together 
by invitation African manufacturers in the 
health-related industries and other professional 
participants working in the fields of regulation of 
health supplies, in distribution and in industrial 
support in African countries. Researchers 
engaged with the pandemic manufacturing 
response in India and in Africa were also invited. 
Beforehand, 17 participants provided notes 
beforehand of the key points they wished to 
make, and then took part in a detailed discussion 
over three sessions. The Appendix to the report 
contains a partial list of participants: those 
happy to have their name included. The report 
has been sent for comment by all participants 
before publication. We are most grateful to all 
participants for their time, contributions, further 
comments, and commitment to addressing these 
complex realities. 
Participants argued that the distinctive local 
concerns under Covid-19 conditions should be 
a loud wake-up call for African and other low- 
and middle-income countries to pull together 
the policies and instruments for supporting local 
industry, science and health in order to strengthen 
the security of supply of pharmaceuticals, 
vaccines, medical devices and other essential 
requirements for local healthcare. The central 
argument that emerged is that a broad-based 
industrial structure is critical for local health 
security – and hence global health security during 
pandemics. Furthermore, building a sustainable 
local health-industrial complex also contributes 
strongly to broad-based industrialisation in Africa.
This report captures some of the contributions and 
debates from the webinar, identifying lessons for 
the future. The next section outlines the reported 
experiences of African manufacturers. The core 
of the report is then an overview of the issues 
and themes emerging from the webinar debate 
on African manufacturing for health in the time 
of Covid-19, as a contribution to policy thinking 
and research. This is followed by a section 
reflecting on learning from the distinctive Indian 
experience and the scope for greater India-Africa 
collaboration.  The final section reflects on the 
understandings of ‘policy’ that help support the 
effective and sustainable development of the 
African health-industrial complex.  This is critical 
for local health security and has cumulative effects 
on global health security. 
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2. African manufacturers’ pandemic experience
1 See for example reported views in Mackintosh, M., Mugwagwa, J., Banda, G. and Tunguhole, J. (2017).
2 See Chazan, G. (2020).
‘For local manufacturers generally it’s been a 
negative experience.’ 
(East African pharmaceutical manufacturer)
‘Great what people have been able to do – 
highlights innovation of African companies to use 
what they’ve got and go for it.’
(West African textile manufacturer)
Both the above statements were widely endorsed 
in the webinar by those with direct experience 
of manufacturing in sub-Saharan Africa during 
the Covid-19 pandemic. The immediate negative 
impact of the crisis was immense across health-
related manufacturing on the subcontinent. 
However, the pandemic also opened spaces for local 
manufacturers to show what they could achieve 
under pressure to support fragile health systems in 
a process of rapid scarcity-induced innovation.
2.1 Negative pressures
‘Africa found itself inevitably at the back of the 
queue for all product supplies.’
(Southern African pharmaceutical 
manufacturer) 
Many African stakeholders have been warning for 
years1 that in a global pandemic, African needs 
would be sidelined in a global nationalistic rush 
to buy up essential supplies. In 2020, it happened. 
As the pandemic began, not only did imports 
of essential items dry up, but supplies of key 
inputs to local manufacturing were also cut off by 
competition from large-scale buyers with deeper 
pockets, while prices of inputs shot up (Box 1). 
That immediate supply chain collapse 
through competition was exacerbated by the 
disappearance of flights and escalating freight 
costs for remaining cargo capacity. The sharp 
financial squeeze on firms was aggravated 
by other sources of financial loss: private 
debtors and governments were slower to pay, 
while remaining input suppliers still required 
pre-payment. 
In a final irony, established firms such as a West 
African textile manufacturer exporting medical 
scrubs to the US found both export markets 
and local production were threatened because 
of a loss of essential inputs, including imports 
of meltblown fabric for face masks from India 
and indeed South Africa. China produces about 
40% of the world’s meltblown fabric, which is 
an essential component of masks: prices are 
reported to have increased as much as 20-fold 
with the advent of the Covid-19 pandemic.2
Box 1: The dangers of import supply chain risk concentration: input cost 
escalation and loss of supplies
A large East African pharmaceutical manufacturer recounted that in November 2019 he made a 
routine order for bulk chloroquine from an Indian company. What followed exemplifies the financial 
squeeze from the input side. The price quoted and accepted was $32 per kilogram, and delivery was 
promised in February – a standard delay given the import logistics. At the end of January 2020, the 
recipient firm checked the order’s progress in a routine manner, and was told ‘No, we cannot commit 
to you now unless you pay $260 per kilogram’. In the face of this 800% price increase, the recipient 
firm cancelled the order. This is ‘one real example of how African manufacturers were being treated’, 
and of the final supply consequences for health services of reliance on a very small number of 
overseas suppliers of key raw materials including active pharmaceutical ingredients (APIs).
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2.2 Constraints on using idle capacity
Many local manufacturers went into the crisis 
carrying spare capacity, which provided 
scope for their ability to respond to suddenly 
escalating local demand. As firms sought to 
use this capacity to expand production, crucial 
constraints included poor quality domestic 
supply options for inputs, substandard imported 
alternatives, and a lack of testing and regulatory 
capacity to allow local firms to bring new 
products rapidly on stream.
Manufacturers identified backward integration 
– by building up local production of high-
quality inputs – as central to local manufacturing 
resilience. Examples given in the webinar of 
where backward integration was particularly 
important included: 
 ● local production of some APIs to break the 
risk concentration on a few overseas, mainly 
Chinese, API suppliers (also a dependence of 
increasing concern in India); 
 ● production of fabric suitable for a wide range 
of medical uses, closely linked to plastic 
manufacturing and processing sectors; 
 ● production of better-quality health-relevant 
packaging, such as sterile plastic bottles and 
other plastic packaging for pharmaceuticals. 
Manufacturers also identified the emergence of 
substandard new suppliers during the pandemic, 
with resultant rejection of outputs and financial 
loss, as a persistent challenge. One manufacturer 
argued that corrupt practices of kickbacks are 
typically more prevalent for import contracts 
than for locally sourced goods (given the lesser 
ease of shifting local currency payment abroad), 
which incentivises continuing national import 
reliance. More than one producer noted quality 
certificates, such as CE certification, could be 
and were being forged and were hard to check, 
indicating the need for greater local expertise, 
training and policing of standards.
The key term that recurs in these experiences 
is quality. All healthcare supplies need to be 
quality-assured, but when the Covid-19 crisis 
hit, the weakness of crucial testing capabilities 
across Africa quickly became a constraint for 
repurposing idle capacity. There was a need, one 
manufacturer argued, for ‘backwards integration 
to build resilience all the way down the [supply] 
chain.’ To do that, testing capability and 
accreditation are key. 
Testing capability is not missing entirely, but it 
is over-specialised and needs a broader base. For 
example, a medical, sterile, clean room-produced 
face mask must be sent to the US or Europe 
for quality testing at a current cost of around 
$3,500. One manufacturer noted that there are 
many internationally recognised testing houses 
present in African countries, but they were not 
necessarily offering the needed services. Ghana, 
for example, has an internationally accredited 
testing facility to do all the testing for the mining 
industry but it has not expanded its facilities to 
test other items. 
Other countries such as Zimbabwe also have 
metrology departments and in-house testing 
facilities for some enterprises that require 
flexibility and accreditation. Facilitating the 
ramping up of local testing, certification and 
accreditation, and their flexible repurposing, 
would in turn break blockages which obstruct 
the repurposing of spare manufacturing capacity 
during crises – and in more normal times. 
2.3 Creative manufacturing 
responses: local facilitators
In the face of all these constraints, local 
manufacturers have nevertheless managed 
to respond creatively across many African 
countries. A key facilitator of these responses has, 
as a Southern African manufacturer observed, 
been the willingness of local producers to share 
technology and to increase production of critical 
products where equipment complementarities 
and technology transfer were possible. Public-
private collaboration has also emerged, tackling 
what one manufacturer called ‘prohibitive 
procurement regulations’ and finding methods to 
facilitate innovation (Box 2).
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Webinar participants noted an impressive list 
of products with which African manufacturers 
responded to Covid-19 requirements at 
speed, through scaling up and product 
innovation. It includes (but is not limited to): in 
pharmaceuticals – dexamethasone, paracetamol 
and azithromycin, all used in Covid-19 treatment 
and all widely available in generic formulations; 
sanitisers and decontaminants; masks, gloves, 
overshoes, face shields, medical scrubs, PPE 
of various quality including medical grade; 
ventilators designed and made from scratch; viral 
transport media and sterile swabs; individual 
and laboratory test kits; and clean room 
production facilities for medical clothing. Some 
of the innovation was strikingly fast, such as the 
production of Nigerian ventilators from design to 
build; and the development of rapid polymerase 
chain reaction (PCR) test turnaround, by ‘people 
who weren’t given the opportunity to innovate 
in a pre-Covid-19 world’ (Southern African 
manufacturer).
Box 2: Cross-sectoral collaboration as key to rapid local response: sanitisers 
and test swabs
Two essential Covid-19 supplies were hand sanitisers for very widespread use and swabs for 
Covid-19 testing. A participant described a cross-sectoral collaboration between an East African 
medical research institute, other government regulatory bodies, and firms in several industrial sectors 
to meet local demand when imports were suddenly unavailable. The research institute already 
produced sanitisers in collaboration with a local manufacturer. When Covid-19 hit, all inputs went 
out of stock. Scaling up production required ethanol from local sugar producers to be applied to 
sanitiser production; a second pharmaceutical company was brought in to add capacity; and a local 
plastics firm scaled up bottle production and created a cap redesign to replace the unavailable pump 
delivery system previously imported from China.
A comparable collaboration between the medical research institute and a textile manufacturer 
previously producing ear buds adapted the manufacturing process to local production of swabs. 
The researchers worked with the firm at all stages to ensure the swabs met the required standards, 
including finding sources of nylon, testing the effectiveness of flock heads since brush heads could 
not be produced, and ensuring sterilisation. At the same time, the research institute scaled up its 
existing in-house production of viral transport medium (VTM) (previously made for research use) by 
repurposing an existing production line for bacterial culture media to produce VTM for transporting 
swabs to the laboratory. 
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3. Core lessons: key themes 
3 See African Union (2012).
4 See also the contributors to Mackintosh, M., Banda, G., Tibandebage, P. and Wamae, W. (eds) (2016a).
5	 Personal	communication	between	the	authors	and	industry	contacts	indicate	that	while	Zimbabwe	was	the	first	African	country	to	locally	
manufacture generic ARVs in the early 2000s, they have fallen behind in the portfolio of latest ARVs on the market. Similarly, South 
Africa	had	institutions	that	focused	on	different	types	of	vaccine	manufacture,	yet	in	the	1990s	most	of	these	were	shut	down,	resulting	in	
institutional memory loss.
The telling examples of manufacturing creativity 
described above relied centrally on what had gone 
before. Countries that were quick to repurpose 
were those that already had some hardware. 
African manufacturing associations had been 
working with governments for many years to 
promote the importance of local manufacturing 
for health in an era when much ‘global health’ 
policy appeared premised on the assumptions 
that medical health technologies were readily 
available commodities, that utilisation and access 
could be generated in a timely manner from global 
pharmaceutical value chains, and that ‘global’ 
advances in knowledge benefited all. 
Long-term initiatives, including through the 
Pharmaceutical Manufacturing Plan for Africa,3 
had challenged this perspective.4 Webinar 
participants noted that there has been a definite 
uptick in employment and value added in local 
manufacturing since the Plan was endorsed by 
Heads of States and governments in Accra in 2007. 
From the very rich webinar debate on learning to 
date, we have pulled out some key themes, with 
the aim of reframing thinking on the importance, 
and facilitation, of local manufacturing for health 
in Africa. Figure 1 sets out these key themes 
and interconnections across the top two layers. 
We summarise them below under four headings 
and return in Section 5 to the policy implications 
developed in the third row of the figure.
3.1 Broadening and deepening 
the industrial base and reducing 
concentration risk through local 
suppliers, industrial collaborations 
and backward linkages 
‘When we talk about manufacturing for health 
we need to think [also] about allied sectors … the 
automotive sectors for reaching remote areas, the 
repackaging of containers, the cold chain and so on.’
(Indian engaged academic)
Industrial and supply capabilities relevant to the 
crisis were centrally rooted in ‘hardware’ such 
as existing manufacturing plant investment. 
Countries that were able to do most had a 
broader industrial base and a resultant capability 
to collaborate across industrial sectors to bring 
new products to market. 
Evidence from Indian colleagues in the webinar 
suggested that there is a cumulative aspect to 
this industrial collaborative capability, since 
cross-sectoral collaborations occur when new 
products are successfully brought to the market. 
These experiences in turn generate co-learning 
opportunities for industrial improvement, 
such as between the packaging industries and 
pharmaceuticals when considering injectables or 
parenterals – as illustrated by a historical case of 
a Zimbabwean company collaborating with the 
plastics manufacturing industry in production 
of packaging.
Successful industrial development requires 
firms to have learned to compete effectively 
among themselves and externally, and also 
to collaborate locally in order to co-learn and 
co-solve both old and new problems to serve 
new markets. One lesson from industrial history 
is that this innovative capability is grounded 
in the generation of local knowledge over time. 
This is knowledge that needs recharging with 
new activity and which, if not constantly used, 
will face knowledge depreciation – as occurred 
in South African vaccine manufacture and 
Zimbabwe antiretroviral (ARV) manufacture.5
Industry associations can act as brokers or 
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renewal and promote linkages between critical 
sectors, and can signal through policy debate 
where different sectors’ interactions are 
increasingly important. For example, new tools 
such as artificial intelligence (AI) and machine 
learning will play a significant role in promoting 
efficiencies and with performing dangerous 
routines, as is characteristic of oncology drug 
manufacture where automation decreases the 
risk of exposure to toxic substances for workers. 
Industry associations can also shape the direction 
for linkages and network formation. While 
the Indian experience suggests that building 
these links has been particularly challenging 
in the medical device and diagnostics fields, 
industry associations in India have responded 
to the pressures of Covid-19 by bringing 
together start-ups and smaller firms with larger 
manufacturers to produce ventilators and 
protective equipment. It can be a challenge for 
particular sub-sectors to preserve knowledge 
accumulation that is based on cross-sectoral 
collaboration, since some collaborations will be 
transactional and may not continue once a crisis 
has passed. Governments may need to find ways 
to support local cross-sectoral industrial clusters 
to sustain local learning and capabilities.
Webinar participants also recounted examples 
of the concentration risk exposed by the Covid-19 
pandemic. Concentration risk implies reliance on 
one or a small number of suppliers, generating 
the risk of a sharp cut-off through loss of those 
suppliers, vulnerability to monopolistic input 
pricing and resultant financial loss (Box 1). 
In pharmaceuticals, a pointed example of 
concentration risk was identified in the webinar 
with reference to the global production of APIs. 
Indian pharmaceutical firms and the world as a 
whole depend heavily on API production in China. 
From a perspective of business and health systems 
risk and resilience, there is a need to mitigate the 
systemic risk generated by this concentration. An 
adverse event in China will feed on that risk, and 
ricochet around all pharmaceutical manufacturers. 
Hence, decentralising API and excipient 
manufacturing is recognised as a strategic move 
for health security: both African and Indian 
companies need to rethink the scope for local API 
and excipient production. 
A Southern African manufacturer argued that 
there are now real technological opportunities 
in this field.  Industry is shifting away from the 
‘cathedral model’ of imposing, capital-intensive 
and large-scale plants towards a more modular 
approach to manufacturing and associated 
automation that generates opportunities 
to produce APIs and excipients locally at 
appropriate scales for local consumption.
There is a clear need to broaden the health 
industries’ industrial base in Africa, including 
in medical devices and diagnostics. Perhaps the 
greatest technical challenge lies in development 
and manufacture of biologicals (including 
vaccines) as well as associated regulatory 
capabilities. The continent has only four vaccine 
manufacturers, in Egypt, Tunisia, Senegal and 
South Africa. The technologies they are using 
may need to be upgraded and they may also 
need to adopt emerging platform technologies 
such as those based on messenger ribonucleic 
acid (RNA) or recombinant protein. The South 
African government has set aside some funds to 
support scale-up of local vaccine manufacture. 
There may be room for South-South learning 
from India, which has made strides in biosimilars 
and vaccine manufacture.
3.2 Building collaborative 
capabilities engaging multiple actors: 
private sector, government, and 
public‑private partnerships (PPPs)
‘Medical devices and diagnostics … have been 
neglected in India … If you are going to grow the 
sector it will require testing facilities, access to 
funding, planning support, all of that.’
(Indian engaged academic) 
In addition to ‘hardware’ and industrial cross-
sectoral collaboration, countries that have 
been able to react fast have displayed capacity 
to collaborate, co-learn and co-solve old and 
new problems across industry, academia and 
government. The example of collaboration in 
Box 2, which brought in relevant government 
ministries to tackle an industrial collaboration 
challenge, leveraged production and innovation 
capabilities developed for public clinical research 
in order to scale up commercial production 
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for public health. This provides evidence that 
bringing together different industrial and 
government sectors is important for solving 
immediate production problems, as well as for 
longer term policy learning and influence. 
Collaboration can leverage existing linkages 
and generate new collaborations to overcome 
inertia that accrues due to lack of trust between 
and among institutions and actors. There is 
good evidence that crises on the pandemic scale 
can help to generate innovative collaborations 
to support a response. The unsolved challenge, 
not well addressed in the webinar, is this: how 
do stakeholders (including industry, academia 
and government) generate and sustain the 
momentum required to purposefully establish 
linkages and collaborations outside of crisis-
driven and serendipitous linkages?
Literature on learning6 posits that the greatest 
opportunities for learning occur through 
interactions at disciplinary boundaries. Linkages 
and collaborations are therefore critical for the 
trans-disciplinary learning central to solving 
complex problems. How can we ensure this new 
learning is sustained?
The webinar explored and discussed existing 
facilitating mechanisms for local pharmaceutical 
production that had been built up in and across 
African countries pre-Covid-19. Transnational 
facilitation included the work of the African 
Union’s Development Agency (AUDA) and 
the New Partnership for Africa’s Development 
(NEPAD) on regulatory harmonisation, and the 
work of the Federation of African Pharmaceutical 
Manufacturers Associations (FAPMA).
National examples cited included pharmaceutical 
parks with infrastructure investment in Ethiopia 
to facilitate foreign direct investment, and a plan 
for a pharmaceutical park in Nigeria. Preference 
for local tendering has been brought in for a 
range of pharmaceuticals in Uganda, alongside 
regulatory efforts to create a level playing field for 
manufacturers with Indian exporters. Ethiopian 
incentives for investment in pharmaceuticals 
6 See for example Lajoie and Poitras (2017).
7 Mackintosh et al. (2016a, 2017).
8 Mackintosh, M., Tibandebage, P., Kungu, J.K., Njeru, M.K. and Israel, C. (2016b) .
include advance payments for orders and tax-free 
loans and tax holidays for new investments. 
Tanzanian incentives noted included: reductions 
in corporation tax for the first five years for 
pharmaceutical manufacturing investors; price 
preferences in public procurement for local 
manufacturers; lower registration fees; and the 
waiving of Good Manufacturing Practice (GMP) 
inspection fees for local manufacturers. 
3.3 Re‑thinking the role of the 
public health system in industrial 
development: innovative 
procurement, assured markets and 
technology shaping
‘In most countries … manufacturing decisions are 
in the Ministry of Industry or Trade … Ministries 
of Health tend to make procurement decisions 
ignoring the decisions their colleagues in Industry 
are making … Convergencies between these two 
tend to be very weak.’ 
(Southern African engaged academic)
The authors of this report have previously 
argued,7 with many others, that building a strong 
industrial supplier sector to strengthen and secure 
local healthcare requires sharply rethinking 
the nature and role of public sectors in health 
systems in relation to those industrial suppliers. 
It is useful to think of the health sector as itself a 
major service industry that is generally in mixed 
public-private ownership; closely integrated into 
a health-industrial complex in which industrial 
development is strongly shaped by public and 
private health spending.8
This framework challenges a passive view of health 
systems as merely purchasers of items designed and 
produced elsewhere, recognising instead the iterative 
processes through which health technologies are 
developed and adopted. This framework also links 
up to a decolonisation agenda where the framework 
of the health-industry complex returns agency, 
power and leverage to the local health system – both 
in terms of shaping dialogue, and the trajectory that 
should be taken in solving local health challenges. 
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The health sector has purchasing power, power 
of technology choice, and technology adoption 
options. It therefore shapes who supplies what 
technologies, and by so doing it shapes the health 
technologies supply terrain. Examples shared 
in the webinar and discussed above illustrate 
local moves away from procurement processes 
that focus only on immediate price and towards 
addressing cash flow and the competitive 
requirements of emerging industrial clusters. 
Local industry has demonstrated during the 
Covid-19 crisis that local industrial capabilities 
and shorter supply chains really do produce a 
more agile response in medical emergencies. 
Local decisions on procurement, technology 
choice and adoption shape complementary 
sectors of local industry. The health sector is a 
large and important recipient of public funds; 
expenditure that governments can leverage as 
part of their industrial policy to support local 
industry beyond times of crisis.
From this perspective, a potent role for 
procurement as part of an active industrial policy 
lies in de-risking early stages of technology 
development and introduction by assuring 
markets. Advance purchase commitments 
by high-income country governments for the 
Covid-19 vaccines confirmed this crucial role, 
by assuring innovators to invest in vaccine 
development and manufacture.
Participants in the webinar repeatedly noted 
that assurance of market access was a – perhaps 
the – key determinant of willingness to invest. 
This implies that advance market commitments, 
if they are to advance African health security, 
should support market access by emerging 
African suppliers, rather than focusing only on 
established exporters. 
Innovative procurement9 can generate industrial 
innovation through assured markets by 
supporting the following:
 ● Market formation for new products: new-to-
country products or new to the world.
 ● Market signalling mechanisms: assured 
markets to support entrepreneurs’ risk taking 
9 For a further discussion of this concept, see Chataway, J., Banda, G., Cochrane, G. Manville C. (2016) in M. Mackintosh et al. (eds) op. cit.
and investment decisions and assist them in 
proposing attractive projects for financing to 
commercial funders.
 ● Legitimation of local industry: by 
underwriting early technology risk and 
procuring products, the public sector serves 
as a legitimation tool for the diffusion of new 
technologies and innovations.
 ● Financing mechanisms: in countries like 
Ethiopia and Uganda, advance payment and 
local procurement has helped entrepreneurs 
reduce their working capital funding 
requirements and avoid high interest charges 
from commercial banks.
 ● Local preference: as one of the ways innovative 
procurement can be deployed.
The recognition that health spending can effectively 
leverage complementary industrialisation alongside 
greater local health security, while reducing 
external aid dependence, creates an incentive for 
African governments to move towards the 15% 
of public sector budget to be spent on health, as 
agreed in the Abuja Declaration in 2001.
Two further arguments on market shaping and 
public health sectors came together in the webinar 
as participants identified the importance of  
regional harmonisation of regulatory rules and 
processes to support regional and cross-continental 
market integration. Two manufacturers noted that 
the Covid-19 emergency had brought out some 
local ‘nationalistic’ conflicts of interest, leading to 
blocks on intra-regional trade. Non-tariff barriers, 
in particular, were seen to be still bedevilling the 
regional market integration needed for large scale 
industrial investment.
However, an experienced African regulator noted 
that the crisis had focused minds on using the 
capabilities within the existing structures and 
guidelines: for example, existing continental 
guidelines for clinical trials and emergency 
preparedness are being used now for Covid-19 
vaccines preparedness. In addition, using existing 
regulatory structures, African stakeholders have 
been able to establish a continental medical 
regulatory committee – the Africa Medical 
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Products Regulatory Forum. The Forum has 
enabled the production of guidance documents 
for Covid-19 diagnostic tests, medical advice 
and PPE, as well as guidelines which could be 
issued to domestic manufacturers and used to 
report substandard medical products throughout 
the continent. This response capability in 
turn reflects a decade of work in regulatory 
harmonisation through the Medicines Regulatory 
Harmonisation (MRH) initiative10, and the work 
to incorporate the African MRH as a specialised 
arm of the African Medicines Agency (AMA), 
now moving slowly towards ratification. 
3.4 Centres of excellence and 
infrastructure to support quality and 
technological capabilities
‘Centres of excellence should work well in Africa: we 
have a lot of common issues, just needs political will.’
(East African manufacturer)
The discussion of regulation returns us to quality – 
a key aspect of industrial response. Manufacturers 
emphasised the lack of testing institutions 
(Section 2) when testing was needed locally and at 
speed for new products. This stimulated a broader 
discussion of the key role that could be played by 
centres of excellence to support industrialisation 
for health. 
One engaged academic with extensive 
manufacturing experience argued that centres 
of excellence can tackle those problems that 
cannot be solved by emerging industrial clusters, 
because no firm can accumulate all the skills, 
resources and capabilities needed. Furthermore, 
there is an acknowledged lack of patient capital 
for supporting innovation and coping with the 
inherent failure rate accompanying innovation 
efforts. This can also be incorporated within a 
centre of excellence that can draw on in-house 
skills to support investment decisions.
This centre of excellence idea is not new on the 
African continent. One earlier example was the 
African Network for Drugs and Diagnostics 
Innovation (ANDI), an initiative that was not 
10 See Sillo et al. (2020) for a good discussion of the East African MRH.
sustainably funded. ANDI set up Centres of 
Excellence in different countries which were 
intended to serve as ‘nucleation’ centres for 
generating knowledge, accumulating capabilities, 
and transferring the knowledge and capabilities to 
others through inter-organisational collaborations 
(the metaphor of ‘nucleation’ is borrowed 
from chemistry where a crystal is immersed 
in a concentrated solution to accelerate the 
crystallisation process). In this case, a centre of 
excellence can be a starting point – a seed crystal 
– for building and accumulating a range of 
complex technological, innovative and industrial 
capabilities, leading to scale.
The key issues that the centres of excellence are 
intended to address include: nucleation tools that 
generate and coalesce sets of scarce skills and 
capabilities; pulling together patient funding at 
scale that is sufficient for industrial step-changes 
(such as a move to API production); supporting 
product innovation for new markets to gain 
legitimation; and working on market formation 
and integration for entry of new products. 
Centres of excellence can also interact with the 
demands from the health sector to force backward 
integration, for example into APIs. They can 
act as centres for knowledge development and 
diffusion for industrial sectors; they can support 
entrepreneurial experimentation and shape 
direction of technological search; and can foster 
collaborative interaction among industrial firms 
and other stakeholders. 
Recent work by one academic webinar participant 
on regenerative medicine demonstrated that, for 
nascent industries where emerging entrepreneurs 
need to demonstrate proof of concept, innovation 
brokers play a pertinent role in de-risking the 
early stages of innovation, and these brokers could 
be centres of excellence. Stronger integration of 
centres of excellence that focus on health needs 
with countries’ broader industrialisation strategies 
and with stronger commitments to health-
industrial policy collaboration may help to sustain 
existing centres’ effectiveness and generate new 
centres of excellence over time.
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4. Learning from Indian experience
11 Nabar and Brahmo (2017).
Indian participants in the webinar stressed the 
scope for learning from both Indian strengths and 
weaknesses. The Indian pharmaceutical industry 
represents a highly successful case of a developing 
country that has built strong local manufacturing 
capabilities in pharmaceuticals and vaccines 
over the last 50 years. However, similar success 
has not been evident in the medical devices and 
diagnostics industries. Two strong themes – and a 
relevant industrial gap – emerged from the Indian 
experiences of response to Covid-19 and the 
capabilities underpinning them. 
4.1 Broad‑based manufacturing 
capabilities   
‘General manufacturing capabilities – issues of 
process in stocking, ports’ availability, technical 
standards, turnaround times – these are wider 
than the health industry.’ 
(Indian engaged academic)
The first theme was strong support for the 
importance of broadly based manufacturing 
capabilities (Section 3) across diverse sectors, 
in order to develop local healthcare technology 
industries. The broad Indian industrial base 
contributes to sustained creation of local 
engineering knowledge, reliable supply 
chains and opportunities for diversification. 
For example, if an Indian firm wants to make 
injectable pharmaceuticals, one of the many 
plastics manufacturers will be invited in to work 
out how to do it. 
New initiatives are generated from the latent 
capacity and synergy that exists in multiple 
industrial sectors. If there is a drop in demand 
in one sector, then there is scope for companies 
to move into other sectors. The benefit of these 
broad-based manufacturing capabilities was 
evident in the Indian response to Covid-19 when 
the Indian Space Research Organisation (ISRO) 
and automobile firms moved into ventilator 
production. A webinar participant noted a 
parallel experience in Nigeria, which has one of 
Africa’s broadest industrial capabilities, where 
the military developed ventilators. Allied Indian 
industrial sectors, such as the automobile 
or electronic industries, are also critical to 
ensure delivery of medicines, vaccines, and 
diagnostics to remote areas, including delivery of 
pandemic requirements.
Also noted in Section 3 was another critical 
aspect of local manufacturing for health: creating 
linkages among these diverse sectors and setting 
up policies that contribute to developing the 
industrial ecosystem. This activity has, however, 
been severely lacking in Indian industry, clearly 
affecting the growth and development of the 
medical device and diagnostics industries.11 The 
Indian government has imposed high import 
duties on some components such as glass screens 
that can be used in smartphones but also in 
medical devices. While the purpose of high 
import duties is to encourage local production, 
it is hurting the medical device and diagnostic 
industries. Local supplies are limited in scale, 
adding significant delay to production. The 
lack of this sort of ecosystem consideration in 
policy and an absence of sectoral collaborations 
and linkage are affecting the development of 
medical devices and diagnostics sectors in 
India. This raises the question of whether and 
how healthcare as a primary driver can shape 
industrial policy to grow other sectors.
Finally, manufacturing for health should also 
focus on local supply chains, and specific areas 
such as cold-chain mapping and delivery 
mechanisms. Webinar participants observed 
that most discussion in this area has focused 
primarily on economic and technical challenges 
associated with setting up local manufacturing 
plants, but prior to Covid-19 little attention was 
paid to cold-chain storage and delivery facilities 
in India.
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4.2 Contestation, policy literacy and 
problem-solving	agility 
‘Civil society and scientific community 
engagement play a very important role in keeping 
policy-makers on their toes.’
(Indian engaged academic)
The second theme may be less familiar. Most 
studies of the development of technological 
capability in the Indian pharmaceutical and 
biotechnology industries credit government 
policies, such as the adoption of weak patent 
laws in 1970 which created a network of research 
laboratories, and the setting of public sector 
firms to produce pharmaceuticals locally. Public 
sector units and research institutes created the 
knowledge base that provided a foundation 
for the future development of the Indian 
pharmaceutical industry, while the Patents Act 
of 1970 protected local pharmaceutical firms 
and facilitated the building of India’s reverse 
engineering skill sets.
However, what remains neglected in academic 
and policy discourse is the critical role of 
contestation in the creation of policy frameworks 
that supported the development of Indian 
local health industries. Contestations among 
various stakeholders – within what one 
webinar participant described as India’s ‘noisy 
democracy’ – contributed to policy literacy, 
learning and problem-solving agility among 
Indian policy- and decision-makers. The politics 
of contestation is evident in the development 
of industrial policy and negotiations of 
relationships with the World Trade Organization 
(WTO) that have helped to build the sector. It 
was argued that the resulting policy literacy 
and learning provided scope for  challenging 
discussions and serious engagement from a 
diverse set of stakeholders about how institutions 
should be built. Civil society organisations and 
networks (including science associations and 
industry associations) significantly contributed 
to the debate and to promoting Indian local 
production and collaborations. 
For example, Indian healthcare technology 
industries are represented by associations that 
cater to various interest groups such as: small 
firms, overseas multinational corporations 
(MNCs) and local MNCs. They are represented 
by industry-specific associations such as the 
Indian Drug Manufacturers Association (IDMA), 
the Organisation of Pharmaceutical Producers of 
India (OPPI), the Association of Biotechnology 
Led Enterprises (ABLE) and the Indian 
Pharmaceutical Association (IPA), along with 
umbrella organisations such as the Confederation 
of Indian Industry (CII) and the Federation of 
Indian Chambers of Commerce and Industry 
(FICCI). The variety of industry associations 
plays an intermediary role and ensures that there 
is communication between small and medium 
firms, local MNCs and overseas firms, and 
represents their views with government.  Though 
they do not drive policy, industry associations 
are increasingly relied upon to provide policy 
support and insights.
The industry and science associations, along with 
other civil society organisations, have intervened 
extensively in India. Their challenging views 
have shaped the science and technology (S&T) 
institutions and contributed to the development 
of the Indian pharmaceutical industry. Where 
policy convergence in India came about, it did 
so through the constituencies that got together, 
with political contestation playing a critical role 
in harmonisation. These noisy contestations 
significantly contributed to the policy literacy 
and development of consensus-building abilities 
among Indian policy-makers. 
Such policy literacy is increasingly evident in 
decisions taken by the Indian government on 
critical policy issues. These include the signing 
of the WTO Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) agreement; acting 
as the main investor for the setting up of the 
biotechnology industry; issuing compulsory 
licences; and, more recently, incentivising API 
production through policy initiatives. In terms 
of policy coordination, the office of Principal 
Scientific Advisor to government is leading the 
charge with the minister for S&T policy. Many 
specialist positions and empowered groups 
are being set up, but the connection between 
science policy and economic policy is still at a 
nascent stage.
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4.3 South‑South collaboration: a gap 
to	be	filled?	
While there have been sporadic examples of 
India-Africa collaboration in the healthcare 
technology industries, they are on a minimal 
scale. India is a major pharmaceutical exporter 
to Africa but not an important pharmaceutical 
investor, though there have been a few 
investments. This history contrasts with the 
Indian industries’ strategies in Latin America, 
where Indian pharmaceutical firms are setting up 
production facilities to cater to local markets. 
For example, one participant pointed out that in 2020, 
six generic drug makers – Dr Reddy’s Laboratories, 
Zydus Cadila, Glenmark Pharmaceuticals, Torrent 
Pharmaceuticals, Hetero Drugs and Ackerman 
Pharma – signed a deal with Hidalgo State in Mexico 
to set up a large pharmaceutical production and 
logistics cluster to cater for Latin American regional 
needs. The Mexican government has offered the 
Indian generic drug makers preferential status in 
the public procurement of medicines, in addition to 
making it easier to register drugs and to export them 
to other Latin American markets. This has resulted 
in about 21 Indian drug companies establishing 
business operations in Mexico.12
12 See Sukumar (2020).
However, similar interest in setting production 
facilities in African regions seems to be lacking 
among Indian pharmaceutical manufacturers. 
One of the explanations provided by the 
manufacturers is that, like India, African 
markets are low value and high-volume, which 
reduces their attractiveness in terms of making 
greenfield investments.
It is increasingly evident that Indian companies 
are in search of a high-value growth markets 
business model that can distinguish them 
from the growing competition among generics 
firms. Yet, there is an acknowledgement among 
Indian stakeholders that there is further scope 
for collaboration on issues around intellectual 
property (IP), medical device and diagnostic 
industries. For example, India and South Africa 
jointly requested the WTO for temporary 
suspension of certain IP concerning diagnostics, 
vaccines and therapeutics related to Covid-
19. This is an area where African market 
integration, demand shaping and policy shifts 
could change incentives towards more local 
production and technology transfer from India to 
Africa in the medium term.
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5. ‘Staying awake’: building for the longer term
‘In many African countries, barriers to local 
manufacturing aren’t necessarily restricted to 
pharma or health, they are broader barriers such 
as infrastructure …  So we may want to frame our 
work in this broader context.’
(Engaged African academic)
There was broad agreement among African 
webinar participants that Covid-19 had been 
a wake-up call. The problem however, as one 
participant put it, is ‘there have been so many 
wake-up calls. How are the people who have 
been woken up going to stay awake?’
The pervasive and immediate impact of Covid-19 
was felt to have been a particular wake-up 
call for governments about the weaknesses of 
their health systems. One manufacturer argued 
that, for decades, African healthcare has been 
neglected, and then when top government 
officials fell ill, they would ‘hop on a plane’ 
to Europe or Singapore. When Covid-19 hit, 
they were no longer able to do that, with 
tragic consequences for some. This perceived 
‘national disgrace’ (in the words of one African 
manufacturer) has created a new realisation 
of the need to invest in local health systems – 
including their supply chains.
5.1 Issues and options  
An issue can be thought of as a vital concern 
or unsettled problem. In the context of local 
manufacturing for health, issues included 
capabilities in research and innovation, 
manufacturing, regulation, policy and governance, 
finance and sustainable markets. In particular, 
issues relating to policy and governance were 
integral to the overarching narrative emerging 
from our contributors. We sum this up as a need 
for accelerated short-term action, and well-
coordinated long-term national ambition, if the 
aim for local manufacturing for health is to be 
practical, cost-effective and sustainable. 
This summation opens up a range of policy 
options, all of which should broadly result 
in mitigation of the impacts of the pandemic, 
consolidating the capabilities ushered in by 
pre-pandemic and pandemic actions, and 
upscaling and embedding manufacturing 
capabilities within the broader national 
health and industrial structures. Mitigation, 
while discussed only tangentially in the 
webinar, applies to options and actions for 
avoiding further damage from the pandemic.  
Consolidation applies to options and actions in 
the further use and embedding of capabilities 
that have arisen from responses to the pandemic.
Contributors noted the importance of agility 
and adaptability, not just in manufacturing 
capabilities, but in policy and governance 
measures as well. Furthermore, mitigation, 
consolidation and upscaling options exist at 
different points in sectors connected to local 
pharmaceutical manufacturing, but the context for 
implementation and the potential to contribute to 
building sustainable local manufacturing differ 
between sectors and countries. 
This section builds on the broad themes 
emerging from the African and Indian 
experiences to identify some options for African 
countries to emerge from the pandemic with 
stronger health-industry complexes. The bottom 
layer of blue boxes in Figure 1 lists key points 
and interactions in some detail.
5.2 Early priorities for medium‑term 
support
Reflecting on lessons from successes and 
challenges to date, participants identified 
some practical collaborative problem-solving 
achievements that addressed the immediate 
needs of the crisis. Box 2 described one such 
collaborative effort involving government 
ministries and industrial sectors, plus 
researchers. A participant noted that in Ethiopia 
the government had offered tax relief to some 
existing firms to provide breathing space during 
the Covid-19 pandemic. Donors have supported 
immediate needs such as subsidised programmes 
to make medical scrubs in Ghana. 
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Incentivised by the crisis, governments are also 
responding with longer-term thinking. For 
example, South Africa had been importing much of 
its paracetamol, manufactured in India by a South 
Africa-based company. As the crisis bit, the country 
was (like others) ‘within five weeks of running out 
of paracetamol’. The Ministry of Health responded 
with a task force to look at localisation of supplies 
and market access for local producers.
Several key areas for a medium-term policy focus 
emerge from the manufacturers’ concerns. One 
is the testing-regulation-accreditation process. 
While the need to improve regulation is a long-
term concern, the pandemic has focused attention 
on local testing resources. It highlighted the need 
to invest heavily in the skills and autonomous 
institutions that can test products to international 
standards, without the need for transport to 
Europe or the US. This gap was noted by several 
manufacturers as posing a major hurdle for 
innovators in African countries – from textiles to 
engineering.
A second is finance: both targeted support 
for firms and sectors, as in the long-proposed 
pharmaceutical fund, and major funds for 
13 United Nations Economic Commission for Africa.
infrastructure investment. Two sets of comments 
from manufacturers illustrate their thinking. 
One is around the importance of targeting funds 
to specific firms that can innovate and scale up 
fast, rather than, as one put it, ‘spray and pray’ 
funding, or funding open to all comers. 
On this point, one manufacturer remarked on the 
billions of dollars going upfront to companies to 
deliver vaccines with no guarantee of success:  
‘Wouldn’t it have been nice if that model had 
been used in Africa, to say “Look, we need 
masks, let’s bring some technology quickly and 
give lots of money to three or four companies in a 
region and say, please do the masks?”’. 
The second set of comments on finance also relate 
to the extent to which funds can be found for 
this type of support within Africa. One African 
manufacturer focused on this issue. Within weeks 
of the pandemic starting, he noted, ‘the African 
Development Bank and the African Development 
Bank and UNECA13 had put together a 7.5 billion 
dollar fund to deal with Covid-19 – but where was 
it when we needed help to build the capacity?’ He 
concluded that the money is there on the African 






























































































































It is our hope that the pervasive impact of the 
pandemic will lead to an alignment of funding 
priorities with the industrial development needs 
of African countries.
5.3 Sustained investment in 
institutional architectures towards 
building cumulative institutional 
memories
Institution-building for effective policy is an 
under-studied phenomenon – especially in the 
health industries in African contexts. We use the 
word ‘institutions’ in this case to refer to norms, 
ways of doing things or the way the ‘game 
is played’.14 Institution formation, that is the 
cumulative process of acquiring capabilities and 
institutional memory, and the ability to form and 
reformulate institutions to support technology 
development and innovation, has been studied 
more extensively by innovation scholars looking 
at, for example, the manufacturing sectors in the 
western hemisphere. 
Three key institutions emerged in a particularly 
intriguing manner in the webinar:
1. The institutions of governance, through 
standards and regulations.
2. Policy as institutions of development action, 
resource allocation and directionality, with 
elements of political economy emphasised in 
positive political contestations.
3. The institution of brokers and intermediaries 
as exemplified by industry associations.
Standards and regulation were accepted as 
key governance tools. Participants observed 
that there are certain immutable areas such as 
technical specifications and safety, while areas 
such as administrative competencies can be 
gradually improved.  Policy was noted as an 
area that needs more research and interrogation, 
particularly with regard to policy as action (not 
just as intent). This includes policy learning 
from other sectors and countries, as well as 
deconstructing the linkages between policies 
and their supporting legal instruments and 
14 Nelson and Sampat (2001).
15 Garud, R., Hardy, C. and Maguire, S. (2007).
administrative tools that drive execution. 
We suggest that the pandemic could be an 
opportunity for what some scholars have termed 
institutional entrepreneurship; 15 purposive 
actions by individuals and organisations to 
intentionally deviate from existing structures 
and processes.
The momentum for local production witnessed 
in response to the Covid-19 pandemic represents 
an opportunity for a systematic structural 
transformation to higher productivity, higher 
knowledge and higher-skill pharmaceutical 
sector activities for African countries and other 
low-income economies. We see this as a key 
moment to move from responsive or emergency-
induced manufacturing to sustainable and 
adaptive local manufacturing for local health. 
Through a carefully crafted and implemented 
capabilities escalator which links research, 
manufacturing, regulation, financing and 
market capabilities, with policy and financing 
as overarching themes, there is possibility 
for transformative and integrative local 
manufacturing for health in Africa. 
As highlighted in earlier sections, the extent 
to which sub-Saharan African countries 
can effectively harness and apply historical 
and current momentum towards sustained 
manufacturing capabilities depends on the 
nature and effectiveness of governance norms 
and the instruments and structures that they 
establish.  This means aligning the design 
and connection between policies and legal 
frameworks governing local pharmaceutical 
manufacturing with national goals of health 
security and sovereignty. 
One webinar contributor noted the difference 
between ‘capital P’ written policies, and ’small 
p’ policy actions to support local production. 
An African regulator commented that ‘Africa 
isn’t short of policies at national, regional and 
continental level’ to advance innovation, local 
production or the regulation of medical products. 
An African manufacturer commented that 
policies that ‘sound good’ may lack the legal 
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instruments for implementation – or policies 
or political directives may even contradict the 
legal mandate of implementing institutions – so 
that officials lack protection and may comply or 
be fired.
Building solid institutional capabilities is 
therefore a long-term process. While national 
legislators are, as a participant noted, key to 
this process, a regulator commented that in 
her experience, there are important mutual 
interactions between regional and national 
action. Where there are capacity limitations at 
a national level, regional integration can play a 
critical role to assist in building national capacity. 
As an African regulator remarked: ‘Once you 
harmonise those [regional] standards you 
provide a platform where countries with less 
capacity can come through the regional platform 
to learn and build their [national] capacity.’
Others identified supports for building 
capacity, including ‘robust advocates’ from civil 
society to enhance accountability in terms of 
implementation of policies over time. Developing 
a common language and understanding among 
the variety of stakeholders was also identified as 
key. Ethiopia was cited as an example of a long-
term concerted effort to effectively link national 
strategies to manufacturing plans and regulatory 
institutions, creating a common language and 
position from which to advance practical policy 
action.
Covid-19 responses have generated a good 
deal of potential for future action in the form of 
resources, structures and expertise. Coordination 
has emerged as an increasing problem, however, 
since stakeholders have different priorities 
and competing interests. An example has 
been clinical trials and production of Covid-19 
vaccines for Africa: the Africa Centre for Disease 
Control has brought together key stakeholders, 
but coordination remains problematic. Similarly, 
there are many bodies doing procurement, 
some overlapping. Learning lessons for future 
coordination and institution building will be both 
difficult and important.
The analysis above highlights the importance 
of engaging with policy-makers if appropriate 
governance regimes – particularly policies, 
regulation and legislation, are to ensure 
sustainable, transformative and integrative 
manufacturing capabilities in Africa. Research 
support that generates an active push for 
different stakeholders to work together might 
help support that long-term goal.
25
6. Conclusions and areas for future research
This report has analysed and attempted to 
synthesise highly insightful discussions, rooted 
in African and Indian experiences, which took 
place in a webinar on local manufacturing for 
health in the time of Covid-19. In line with 
earlier arguments by many of the participants, 
these discussions highlighted the importance of 
local industrial and institutional capabilities in 
ensuring local (and hence global) health security. 
The pandemic has not only exacerbated health 
and socioeconomic inequalities, weakened 
national health systems, and significantly slowed 
down economic growth attained by sub-Saharan 
Africa in the past two decades or so. It has also 
exposed a tough road to recovery ahead for the 
countries in the context of depleted capabilities. 
The distinctive local concerns from Covid-19 
should be a loud call to ‘wake up and stay awake’ 
for countries (especially low- and middle-income 
countriesto pull closer together to implement 
policies for industry, financing, science and 
health in order to strengthen the security of 
essential supplies for local healthcare. 
The rapid and impactful responses witnessed 
in some African countries have generated, as 
one participant noted, some ‘superb products’, 
which were created by people who had not had a 
chance to do so in the pre-Covid-19 world. How 
are these opportunities to be sustained through 
better priorities – a point many participants 
made – in the application of resources, structures, 
linkages, political will and expertise? 
A key message is that sustaining this momentum 
requires building institutional mechanisms that 
ensure consolidation and coordination of broad-
based industrial and regulatory capabilities and 
local agency, and also generate the contestation 
that holds these processes to account. Covid-19 
has demonstrated forcefully that local 
manufacturing capabilities are critical for public 
health security, with particular reference to the 
health needs of sub-Saharan Africa. Learning 
from the pandemic experience, sustaining local 
opportunities for innovation and building a 
broad manufacturing base, while sustaining 
multi-sectoral collaborations, are all central items 
in that agenda. 
The webinar discussions also highlighted several 
areas for future research.  Here, to stimulate 
further thoughts and work, are some aspects of 
that research agenda and questions that need 
more unravelling. 
 ● How can policy as action be re-imagined, 
taking a holistic and pragmatic approach 
to conceptualise all the soft and hard 
infrastructures required to support the 
development of medium- and long-term 
local health-industrial complexes, in order to 
support local health security and in turn global 
health security?
 ● Who are the stakeholders required to 
ensure the active policy contestation that 
continuously shapes local health security 
based on local industrial capabilities?
 ● What new innovative procurement policies 
are required to use public health spending 
as active industrial policy for supporting 
the growth of a broad industrial base that 
supports health?
 ● How can agility and adaptability be built into 
local health-industry complexes to prepare for 
future medical emergencies?
 ● How can regulation and governance be made 
fit for purpose for emerging sectors and for 
pandemic situations?
 ● How can the pharmaceutical sector diversify 
the concentration risk in the supply of key raw 
materials and attendant logistics challenges 
when countries lock-down?
 ● How can industry associations garner more 
clout and impact in raising key technological 
and innovation challenges that need to be 
addressed?
This is a critical research agenda. Despite much 
effort, health and manufacturing research for 
policy is still siloed into separate spheres of 
thought, research design, publication, impact 
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processes and policy debate. Can Covid-19 
finally act as the catalyst to break through those 
barriers and pull together research on mutually 
supportive routes to integration of industrial, 
institutional and health policies for managing 
public health security risks in African countries? 
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Appendix: Partial list of participants
The table below lists those participants in the webinar Local manufacturing for health in the time of 
Covid-19 on 28 October 2020 who agreed to include their names in this report. 
Name Position, organisation
Mr Dinesh Abrol Professor, Institute for Studies in Industrial Development, India 
Mr Harvinder Alag Director, Shagun International Pharmaceutical and Educational 
Consultants Ltd., Tanzania
Mr Aaron Bailey‑Athias Senior	Communications	Officer,	ODI	and	Development	and	
Economic Growth Research Programme (DEGRP), UK
Dr	Geoffrey	Banda Lecturer in Global Food Security and Innovation, and Deputy 
Director – The Innogen Institute, University of Edinburgh, UK
Prof. Joseph Fortunak Professor of Chemistry, Howard University, US
Dr Dinar Kale Senior Lecturer in Innovation and Development, Open University, UK
Ms Julia Kraetke Manufacturing Africa Adviser for Ethiopia and Rwanda, UK Foreign, 
Commonwealth	and	Development	Office	(FCDO),	Ethiopia
Ms Grace Kramer Manufacturing Africa Adviser, UK Foreign, Commonwealth and 
Development	Office	(FCDO),	Nigeria
Prof. Maureen Mackintosh Professor of Economics, Open University, UK
Mr Dominic McVey Non‑Executive Director, ODI and Ethical Apparel Africa, UK
Mr Nazeem Mohamed Head of Pharmaceutical Sector, Industrial Promotion Services (IPS), 
Aga Khan Foundation, Uganda
Prof. John Mugabe Professor at the Graduate School of Technology Management and 
Research Associate at the Institute for Technological Innovation 
(ITI), University of Pretoria, South Africa
Dr Julius Mugwagwa Associate Professor in Innovation and Development, University 
College London, UK
Mr Emmanuel Mujuru Chair of Board, Federation of African Pharmaceutical Manufacturers 
Associations (FAPMA), Zimbabwe
Mr Janak Nabar CEO, Centre for Technology, Innovation and Economic Research 
(CTIER), India
Dr Skhumbuzo Ngozwana President and CEO, Kiara Health, South Africa
Ms Onyeka Onwuegbunam Vivian African Graduate Scholar 2019, University College London, Nigeria
Ms Keren Pybus Founder and CEO, Ethical Apparel Africa, UK
Ms Louise Shaxson Director of Programme, ODI and Development and Economic 
Growth Research Programme (DEGRP), UK
Prof. Smita Srinivas Professorial Research Fellow in Economics and Development, Open 
University, UK
Ms Cecilia Wanjala Commercial Manager, Production Unit, Kenya Medical Research 
Institute (KEMRI), Nairobi, Kenya
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